Johnson & Johnson MedTech is restructuring its DePuy Synthes orthopedic business, executives said today on a quarterly earnings call with investors.
J&J (NYSE: JNJ) CFO Joe Wolk said the two-year restructuring program will take the orthopedics unit out of “less profitable markets and product lines” to improve the segment’s profitability after it reported 2.6% sales growth in…